ABSTRACT
OBJECTIVE: To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. PATIENTS AND METHODS: Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. RESULTS: 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1 %) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (Pâ¯<â¯.05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (Pâ¯<â¯.05). CONCLUSION: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
OBJETIVO: Analizar la incidencia de la enfermedad del coronavirus 19 (COVID-19) en pacientes consumidores crónicos de hidroxicloroquina. PACIENTES Y MÉTODOS: Estudio multicéntrico observacional retrospectivo transversal en Áreas de Salud de Castilla La-Mancha y distritos sanitarios de Andalucía. De los 4.451 participantes incluidos en el primer reclutamiento se seleccionaron 3.817 sujetos con datos válidos. La variable principal del estudio ha sido la presencia o ausencia de infección por la COVID-19 por diagnóstico clínico, serológico o por reacción en cadena de la polimerasa. Se registraron variables sociodemográficas, clínicas y tratamientos y comorbilidades concomitantes. RESULTADOS: Ciento sesenta y nueve (4,45%) pacientes presentaron infección por la COVID-19, de los cuales fallecieron 12 (7,1%) y 32 (18,9%) requirieron ingreso hospitalario. La enfermedad respiratoria previa se relacionó con la infección por la COVID-19 (pâ¯<â¯0,05). La maculopatía aparece en un 5,3% de los pacientes y está relacionada significativamente con la dosis de hidroxicloroquina consumida (pâ¯<â¯0,05). CONCLUSIÓN: No existe relación entre consumo crónico de hidroxicloroquina e incidencia de la COVID-19.
ABSTRACT
OBJECTIVE: To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. PATIENTS AND METHODS: Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. RESULTS: 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P<.05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (P<.05). CONCLUSION: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , COVID-19/epidemiology , Hydroxychloroquine/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/complications , COVID-19/complications , COVID-19/diagnosis , COVID-19 Testing , Chronic Disease , Cross-Sectional Studies , Female , Humans , Incidence , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Prognosis , Protective Factors , Retrospective Studies , Risk Factors , Spain/epidemiologyABSTRACT
OBJECTIVES: to describe the efficacy and safety of the off-label use of alendronate in the treatment of osteoporosis in children and adolescents. METHOD: a retrospective study (2008-2014) of all patients under 18 years who were dispensed alendronate for this indication. The criteria for initiating treatment were: bone mineral density with a Z-score ≤ -2.5 SD, a past history of bone fractures without a previous traumatism, and persistent pain. The variables collected were: demographic, treatment-related, clinical. and safety data. The treatment was considered to be effective when there was an increase in bone mineral density up to a Z-score > -2.5 SD. RESULTS: a total of 12 patients, 8 of them male, with a mean age of 11 years (± 3 SD), were treated with alendronate. After a mean time of treatment of 2.15 years (± 1.2 SD), there was an increase in bone mineral density in all patients, 9 of which achieved a Z-score > -2.5 SD, so the drug was considered effective in 75% of cases. No patient had bone fractures or expressed adverse effects during treatment. CONCLUSIONS: alendronate increased bone mineral density and was well tolerated in all patients, therefore it could be considered as a therapeutic option in the treatment of osteoporosis in children.
Objetivos: describir la efectividad y seguridad del uso de acido alendronico en el tratamiento de la osteoporosis en ninos y adolescentes, en condiciones distintas a las autorizadas en la ficha tecnica. Métodos: estudio retrospectivo (2008-2014) de todos los pacientes menores de 18 anos a los que se dispenso acido alendronico para esta indicacion. Los criterios para iniciar tratamiento fueron: densidad mineral osea con puntuacion Z-score ≤ -2,5 DE, antecedentes de fracturas oseas sin traumatismo previo y dolor persistente. Las variables recogidas fueron: demograficas, de tratamiento, clinicas y de seguridad. Se considero efectividad del tratamiento al aumento de la densidad mineral osea hasta obtener Z-score > -2,5 DE. Resultados: un total de 12 pacientes, 8 varones, con una media de edad de 11 anos (} 3 DE), fueron tratados con acido alendronico. Tras un tiempo medio de tratamiento de 2,15 anos (} 1,2 DE), se produjo aumento de la densidad mineral osea en todos los pacientes, 9 de los cuales obtuvieron Z-score > -2,5 DE, por lo que el farmaco se considero efectivo en el 75% de los casos. Ningun paciente presento fracturas oseas ni manifesto efectos adversos durante el tratamiento. Conclusiones: el acido alendronico incremento la densidad mineral osea y se tolero bien en todos los pacientes, por lo que se podria considerar como opcion terapeutica en el tratamiento de la osteoporosis infantil.
Subject(s)
Alendronate/therapeutic use , Bone Density Conservation Agents/therapeutic use , Osteoporosis/drug therapy , Adolescent , Alendronate/adverse effects , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Child , Female , Humans , Male , Off-Label Use , Retrospective Studies , Treatment OutcomeABSTRACT
Objectives: to describe the efficacy and safety of the off-label use of alendronate in the treatment of osteoporosis in children and adolescents. Method: a retrospective study (2008-2014) of all patients under 18 years who were dispensed alendronate for this indication. The criteria for initiating treatment were: bone mineral density with a Z-score ≤-2.5 SD, a past history of bone fractures without a previous traumatism, and persistent pain. The variables collected were: demographic, treatment-related, clinical. and safety data. The treatment was considered to be effective when there was an increase in bone mineral density up to a Z-score >-2.5 SD. Results: a total of 12 patients, 8 of them male, with a mean age of 11 years (± 3 SD), were treated with alendronate. After a mean time of treatment of 2.15 years (±1.2 SD), there was an increase in bone mineral density in all patients, 9 of which achieved a Z-score >-2.5 SD, so the drug was considered effective in 75% of cases. No patient had bone fractures or expressed adverse effects during treatment. Conclusions: alendronate increased bone mineral density and was well tolerated in all patients, therefore it could be considered as a therapeutic option in the treatment of osteoporosis in children (AU)
Objetivos: describir la efectividad y seguridad del uso de ácido alendrónico en el tratamiento de la osteoporosis en niños y adolescentes, en condiciones distintas a las autorizadas en la ficha técnica. Métodos: estudio retrospectivo (2008-2014) de todos los pacientes menores de 18 años a los que se dispensó ácido alendrónico para esta indicación. Los criterios para iniciar tratamiento fueron: densidad mineral ósea con puntuación Z-score ≤-2,5 DE, antecedentes de fracturas óseas sin traumatismo previo y dolor persistente. Las variables recogidas fueron: demográficas, de tratamiento, clínicas y de seguridad. Se consideró efectividad del tratamiento al aumento de la densidad mineral ósea hasta obtener Z-score >-2,5 DE. Resultados: un total de 12 pacientes, 8 varones, con una media de edad de 11 años (± 3 DE), fueron tratados con ácido alendrónico. Tras un tiempo medio de tratamiento de 2,15 años (± 1,2 DE), se produjo aumento de la densidad mineral ósea en todos los pacientes, 9 de los cuales obtuvieron Z-score >-2,5 DE, por lo que el fármaco se consideró efectivo en el 75% de los casos. Ningún paciente presentó fracturas óseas ni manifestó efectos adversos durante el tratamiento. Conclusiones: el ácido alendrónico incrementó la densidad mineral ósea y se toleró bien en todos los pacientes, por lo que se podría considerar como opción terapéutica en el tratamiento de la osteoporosis infantil (AU)
